Abstract
In Spain, the management of metabolic dysfunction-associated steatohepatitis (MASH) through lifestyle changes faces challenges due to poor patient adherence, partly explained by a lack of knowledge and insufficient support from healthcare professionals. Multidisciplinary approaches involving hepatology, endocrinology, gastroenterology, nursing, psychology, dietetics, and nutrition have shown effectiveness. In our center, a one-year multidisciplinary structured programme provides a personalized care for MASH and associated cardiovascular risk management. Incorporating the perceptions of the patients into lifestyle interventions may enhance treatment outcomes. The aim of this study is to explore the perceptions, attitudes, needs, and knowledge of the patients with MASH participating in the multidisciplinary MASH-Cardiovascular programme (MASH-CVP) at our hospital. This qualitative study will use semi-structured interviews at two time points: baseline and after completion (12 months) of the MASH-CVP. Interviews will be recorded, transcribed, and analyzed using thematic content analysis. The sample size will be determined by saturation analysis. A pilot study will ensure the interview guide clarity and relevance. The study will provide insights into the perceptions, expectations, attitudes, needs, and knowledge of the patients participating in the MASH-CVP at HSCSP. The findings are expected to inform improvements in the implementation of multidisciplinary care interventions, as well as enhance communication and engagement between healthcare professionals and patients. Future research should focus on exploring barriers and facilitators of implementing these tailored interventions in broader settings, while also incorporating the voices and perceptions of the patients to improve effective communication and engagement with MASH treatment.
Keywords
Background and Study Justification
Metabolic dysfunction-associated steatohepatitis (MASH) represents a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) and is characterized by hepatic inflammation, with or without fibrosis, which can progress to cirrhosis and hepatocellular carcinoma European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO)European Association for the Study of Diabetes EASDEuropean Association for the Study of Obesity EASO, 2024. In Spain, the prevalence of MASH among adults is estimated at 33.0% for significant fibrosis (F2-F4) and 19.4% for advanced fibrosis (F3-F4) (Aller et al., 2024). MASH is also closely associated with metabolic comorbidities, including obesity, type 2 diabetes (T2D), hypertension, and dyslipemia European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO)European Association for the Study of Diabetes EASDEuropean Association for the Study of Obesity EASO, 2024. Dietary and nutritional therapy is the cornerstone of MASH treatment. In Spain, this nutritional approach largely relies on weight loss through the Mediterranean Diet, although long-term adherence remains challenging (Akhlaghi et al., 2020; Hydes et al., 2020; Shea et al., 2023). Only about 15% of patients achieve a 10% weight reduction, as adherence often declines after the first month (Arora et al., 2018). Several barriers have been identified that contribute to this limited adherence, including time constraint, insufficient information, limited health literacy, negative perceptions, comorbidities, limited family support, and complexity (Saddic et al., 2025; Shibayama et al., 2024). In contrast, adherence can be improved by factors such as disease education, motivation, relapse management, positive reinforcement, and psychological or family support (Arora et al., 2021; Gu et al., 2023). Despite this, many individuals with MASH lack sufficient knowledge and awareness about the condition and report insufficient healthcare support, which hinders self-management and increases the demand for information and assistance (Cook et al., 2018; Francque et al., 2021; Jang et al., 2021; Shinde et al., 2024; Stine et al., 2025).
Previous studies emphasize the importance of personalized lifestyle interventions that incorporate MASH patient perceptions, which may enhance treatment outcomes (Boeckmans et al., 2025; Shea et al., 2023; Tincopa et al., 2021). Given the coexistence of metabolic syndrome features and cardiovascular comorbidities as hallmarks of MASH, an holistic and multidisciplinary approach is essential for managing this condition (Kumar et al., 2021; Pieter et al., 2026).
Programmes such as the Innovative Center for Health and Nutrition in Gastroenterology (ICHANGE) at Weill Cornell Medical Center and the Oxford University Hospitals National Health Service (NHS) Foundation Trust (OUH) have advanced team-based models for managing MASH, bringing together specialists in hepatology, endocrinology, gastroenterology, nursing, psychology, dietetics, and nutrition (Kumar et al., 2021; Moolla et al., 2019). These initiatives address key metabolic and behavioral risk factors through comprehensive lifestyle plans, targeted weight loss strategies, and structured follow-up, optimizing both clinical outcomes and healthcare resource use (Kumar et al., 2021; Moolla et al., 2019). Similarly, a multidisciplinary clinic at Penn State Health Milton S. Hershey Medical Center (USA) reported significant improvements in hepatic enzymes, glycemic control, lipid profile, and blood pressure parameters among individuals with MASH (Stine et al., 2025).
Collectively, this quantitative evidence highlights the value of integrated, team-based multidisciplinary care in addressing the multifactorial nature of MASH. Such models appear to enhance patient adherence to lifestyle interventions, strengthen therapeutic trust, and improve communication among healthcare professionals (Carrieri et al., 2022; Gorin et al., 2017; Moolla et al., 2019; Stine et al., 2025). Building on these insights, we developed the MASH-Cardiovascular programme (MASH-CVP) at Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona (Spain), with the aim of improving MASH management within our community (Antentas et al., 2026). This programme began its implementation in 2022. In line with previous studies, quantitative data from our programme showed that although weight loss and nutritional intervention remain the cornerstone of treatment to reduce liver steatosis and fibrosis, most patients achieved their greatest weight reduction during the first six months. However, these improvements were not sustained at 12 months, and no significant additional benefits were observed over time (Antentas et al., 2026).
Most studies on MASH treatment rely on quantitative approaches, which may not fully capture the patient’s perceptions or quality of life improvements insufficiently (Twiss et al., 2023). Quantitative data primarily assess clinical outcomes, but often do not capture the underlying reasons for observed changes, and do not adequately address patient experiences, barriers to long-term adherence, or perceptions of multidisciplinary care. Notably, qualitative research remains limited, mainly focusing on disease nomenclature and diagnosis experiences rather than exploring patient perceptions on multidisciplinary programmes in MASH (Stine et al., 2024; Williams et al., 2025). Moreover, available evidence has largely examined patient perception on diet, weight loss, and exercise in isolation, rather than within a multidisciplinary context (Stine et al., 2024; Tincopa et al., 2021). This gap highlights in the need for qualitative research assessing patient experiences with the advice and interventions provided, and underscores the importance of person-centered approaches that consider patient beliefs, preferences, and motivations regarding lifestyle and dietary changes (Boeckmans et al., 2025; Shea et al., 2023; Twiss et al., 2023).
In this context, several factors may influence adherence to lifestyle recommendations among patients participating in the multidisciplinary MASH-CVP, as quantitative findings indicate improvements in liver health and metabolic comorbidities primarily at 6 months, but not in long term (Antentas et al., 2026). Accordingly, we hypothesize that, at the onset of the multidisciplinary MASH-CVP, patients hold specific expectations, attitudes, and levels of disease-related knowledge, as well as distinct needs for managing and addressing their condition, which may evolve over the course of the intervention and differ by its completion.
Therefore, this qualitative study aims to explore in depth the perceptions, expectations, attitudes, knowledge and, needs of the patients regarding the multidisciplinary MASH treatment. We further hypothesized that participation in the MASH-CVP will lead to changes in the perspectives, expectations, attitudes, needs, and knowledge of the patients regarding the management of MASH, and that their needs evolve over the course of the intervention.
The main objective of the study is to explore perceptions, expectations, attitudes, needs, and knowledge of patients with MASH regarding the multidisciplinary management of the condition, before and after participation in the MASH-CVP at HSCSP in Barcelona (Spain) (Antentas et al., 2026).
Secondary objectives will be: • To examine patient perceptions and expectations regarding the multidisciplinary intervention of the MASH-CVP before and after participation. • To assess the attitudes, needs, and knowledge of patients related to the multidisciplinary approach provided in the MASH-CVP, before and after participation. • To identify areas for improvement in the comprehensive multidisciplinary management of MASH based on patient feedback from the MASH-CVP.
Methods
Study Design
This qualitative descriptive study will use semi-structured interviews to collect data, enabling an in-depth exploration of the main study phenomena (perceptions, expectations, attitudes, needs, and knowledge) among patients with MASH participating in the MASH-CVP. This approach allows for a deeper exploration of the meanings and experiences underlying previously obtained quantitative results (Antentas et al., 2026), providing a more comprehensive understanding of the phenomena (Berenguera Ossó, 2014). The semi-structured interview guide will be developed based on the Theoretical Domains Framework (TDF) of behaviour change, which informs the design of questions and supports the exploration of factors influencing the perceptions, attitudes, needs, and knowledge of the patients with MASH, while maintaining an inductive analytic approach (Atkins et al., 2017). The interview questions will follow a flexible structure and will be continuously refined and adapted throughout the data collection process. This approach will allow the incorporation of patients’ perceptions and the exploration of emerging topics of interest based on the responses of the patients, allowing adaptation during data collection to incorporate the perceptions of the patients and respond dynamically to emerging insights. (Malmqvist et al., 2019). (See Supplementary Material). A pilot study will be conducted to assess the clarity, relevance, and feasibility of the material prior to data collection (Kallio et al., 2016). The study protocol has been prospectively registered in the ClinicalTrials.gov database (NCT07188220).
Study Population and Sampling
The study population will consist of patients diagnosed with MASH who meet all the criteria to be referred to the multidisciplinary MASH-CVP at the HSCSP in Barcelona (Antentas et al., 2026). HSCSP is a tertiary-care hospital that provides specialized, multidisciplinary, and coordinated care for patients with MASH, making it particularly relevant for exploring the study phenomena. Recruitment will follow a convenience sampling approach, including patients who meet the clinical eligibility criteria and are accessible and willing to participate. This approach ensures that the data collected are both relevant and informative for the study objectives.
• Patients who voluntarily agree to participate in the MASH-CVP. • Patients who provide informed consent to participate in the study-specific interviews described in this protocol.
• Patients who do not meet the clinical eligibility criteria for participation in the MASH-CVP.
Study Phases
The study is structured into four distinct phases: 1) pilot study phase, 2) recruitment phase, 3) data collection phase, and 4) data analysis phase (Figure 1). Study phase procedures and expected timeline
Study Pilot Phase
A pilot study will be conducted to assess the feasibility, clarity, and relevance of the proposed semi-structured interviews and sociodemographic questionnaire among patients enrolled in the MASH-CVP at HSCSP. Four patients will be included: two who are currently starting the programme and two who are completing it. This pilot phase will evaluate whether the interview questions effectively capture the intended qualitative data and are understandable and meaningful to patients (Malmqvist et al., 2019; Thorogood, N, 2018). Furthermore, feedback from patients will be incorporated to co-design and refine the interview guide, ensuring that the questions accurately reflect their lived experiences and perceptions (Malmqvist et al., 2019).
Recruitment Phase
The required sample size for the study will be determined through saturation analysis, with patients being recruited until no new or previously unidentified concepts emerge during the interviews, ensuring comprehensive coverage of the research topic (Berenguera Ossó, 2014). A saturation grid will be developed to track and document the emergence of spontaneously mentioned concepts related to the main study phenomena. This approach will help determine the point at which no new information is generated (Braun & Clarke, 2021). To confirm data saturation, each patient’s responses will be analyzed, coded, and compared against the number of new concepts identified in subsequent interviews (Braun & Clarke, 2021).
Patients who agree to participate in the lifestyle programme for the treatment of MASH-CVP at the HSCSP will be invited to take part in semi-structured interviews. They will be informed that their contribution to this study will help improve the management of the programme and future initiatives aimed at treating MASH.
Data Collection Phase: Semi-structured Interviews
Data will be collected through two semi-structured interviews to explore the main study phenomena (perceptions, expectations, attitudes, needs, and knowledge) of patients with MASH participating in the MASH-CVP. These interviews will provide valuable insights, enabling an objective and in-depth analysis of the phenomena under investigation, as well as patient experiences and socio-demographic information before and after the programme (Thorogood, N, 2018).
The data collection phase will consist of two visits: one at baseline (0 months) and another at 12 months. A pre-selection period will take place prior to the baseline visit to confirm eligibility. If the criteria are met, the baseline visit will be scheduled. At baseline, patients will complete a sociodemographic questionnaire and take part in a semi-structured interview will be conducted one to two weeks prior to programme initiation. The interview will take place in person at the study center (HSCSP) and recorded using an institutional Teams account to ensure privacy (Figure 2). Study visit schedule and MASH-cardiovascular programme structure
The second interview will take place one to two weeks after programme completion, either in person or online, depending on patient availability. Any changes in socio-demographic information will be recorded and updated during this interview (Figure 2).
Data Analysis Phase
A thematic content analysis will be conducted following the five steps proposed by Graneheim and Lundman (1) verbatim transcription of interviews, (2) thorough review of the transcripts to capture key ideas, (3) identification and coding of units of meaning, (4) grouping of codes into broader categories, and (5) extraction of main themes. All interviews will first be systematically transcribed, after which the research team will carefully read the transcripts to become familiar with the data. Using qualitative analysis software, two researchers will independently code the transcripts according to a pre-established coding framework. This process involves segmenting the text into meaningful units, coding the content, clustering codes into categories, and analysing each category to derive an integrated understanding of the data. Finally, the research team will collectively review and discuss the findings to enhance credibility, consistency, and rigor through triangulation (Berenguera Ossó, 2014). This approach was selected as it enables a systematic yet flexible identification of patterns across the data, allowing for an in-depth exploration of the perceptions and experiences of the patients who participated in the MASH-CVP (Braun & Clarke, 2006).
Ethics
This study will be conducted according to the Helsinki Declaration (World Medical Association, 2013). It has been approved by the research committee of Hospital de Sant Pau on April 23st, 2025, under the code 25/093 (OBS). The interviews will be conducted face-to-face by a dietitian-nutritionist who is not involved in delivering the nutritional intervention offered at the MASH-CVP at the HSCSP, ensuring independence from the clinical team. All interviews will be audio-recorded with the Microsoft Teams platform provided by the University of Vic – Central University of Catalonia. Audio files will be stored on an encrypted institutional server. Recording then will be transcribed verbatim for subsequent qualitative analysis.
Informed consent will be obtained verbally and written, in a face-to-face baseline visit with each patient. Patients will be fully informed about the study objectives, procedures, minimal risks, and potential benefits before giving their consent.
All personal data will be anonymized by assigning a study code to each patient and all patients will be provided with the study information sheet and the informed consent form. The identity of each subject participating in the semi-structured interview will be coded with a unique identifier, ensuring that it cannot be used to identify them under any circumstances. Additionally, the conduct of this study is expected to pose minimal risks to the patients.
Dissemination Strategy
The dissemination plan includes publication in peer-reviewed journals, presentation of findings at scientific conferences, sharing plain language summaries via institutional websites, providing patients with an executive summary of the study results, and posting updates through relevant social media.
Rigor
The rigor of this study will be guided by the criteria of credibility, transferability, dependability, and confirmability proposed by Guba and Lincoln (Guba & Lincoln, 1994). These well-established criteria offer a framework to ensure that the findings are credible, accurately reflect the perceptions of patients with MASH, and are methodologically rigorous.
To achieve these standards, multiple strategies will be employed. First, data triangulation will be conducted to enhance understanding of the complex phenomena under investigation and to capture the perceptions of patients more comprehensively. Following data collection, patients will be invited to review the preliminary interpretations as part of the member-checking process, providing feedback to ensure that the analysis accurately represents their experiences (Korstjens & Moser, 2018).
Reflexivity will be maintained during data collection, analysis, and interpretation, with the researcher position as registered dietitian nutritionist explicitly acknowledged and its influence on the study considered. Specifically, during the semi-structured interviews, the researcher will take brief field notes using a structured template to document non-verbal cues (e.g., facial expressions, tone shifts, pauses), contextual elements (e.g., interruptions), and initial reflexive impressions, which may enrich the interpretation of the data. After each interview, the researcher will expand and clarify these notes, transforming them into detailed field notes and reflexive memos (Korstjens & Moser, 2018; Palaganas et al., 2017). To support transferability, detailed descriptions of the study context, procedures, and patients characteristics will be provided in all publications, facilitating replication (Korstjens & Moser, 2018; Palaganas et al., 2017).
In line with established qualitative research standards, the study will adhere to the Standards for Reporting Qualitative Research (SRQR) (O’Brien et al., 2014; Tong et al., 2012).
Results
The recruitment phase of the study is expected to begin in March 2026, with completion of intervention recruitment anticipated by June 2027. Data analysis will be conducted between July 2027 and September 2028, as the results from the two semi-structured interviews conducted during the study become available. The findings are expected to be disseminated between late 2028 and early 2029, with a comprehensive report detailing the key results, implications, and recommendations shared with all relevant stakeholders.
Discussion
We expect that patients with MASH undergoing in the multidisciplinary MASH-CVP at HSCSP will exhibit changes in their perceptions, expectations, attitudes, needs, and knowledge before and after the intervention.
MASH is a complex, multi-systemic disease, and lifestyle interventions, particularly those targeting diet and physical activity, have shown to improve the condition and, in some cases, even reverse it (Vilar-Gomez et al., 2015). However, adherence to such interventions can be challenging due to various barriers, which may limit their effectiveness (Francque et al., 2021; Neilson et al., 2021; Schattenberg et al., 2023; Shinde et al., 2024). A key determinant of successful interventions is the active engagement of healthcare professionals. Clinicians and other health practitioners play a critical role as educators, guiding patients to understand the importance of managing MASH and sustained behavioral changes (Boeckmans et al., 2025; Haigh et al., 2019).
In addition, managing MASH requires a comprehensive strategy that includes prevention, diagnosis, treatment, and care, with collaboration among multiple stakeholders within the healthcare system (Boeckmans et al., 2025). A multidisciplinary metabolic clinic approach has proven effective, with patients with MASH demonstrating reductions in liver enzyme levels, liver stiffness, and cardio-metabolic parameters such as cholesterol, glucose, and weight (Schattenberg et al., 2023). However, published studies on the effectiveness of such multidisciplinary treatments for MASH, including dietary and nutritional interventions, have primarily been quantitative (Bischoff et al., 2022; Haigh et al., 2019; Moolla et al., 2019; Policarpo et al., 2022). From a dietary perspective, there is a lack of scientific evidence regarding the factors influencing the long-term adoption and maintenance of dietary changes in patients with MASH, such as those affecting diet acceptability and sustainability (Haigh et al., 2019). This highlights the need for further research into these aspects (Haigh et al., 2019).
Complementing quantitative studies with qualitative research is essential to gain a deeper understanding of how patients experience and perceive lifestyle interventions (Campbell et al., 2024), including their perceptions, expectations, attitudes, knowledge, and willingness to adopt dietary changes to improve their health (Boeckmans et al., 2025). Such an approach allows registered dietitians to design more personalized and effective interventions tailored to individual needs and preferences, while also enhancing communication and the therapeutic relationship between healthcare professionals and patients (Campbell et al., 2024; Pieter et al., 2026). Therefore, qualitative research offers a holistic and detailed understanding of the factors influencing lifestyle management in MASH.
Potential Limitations and Challenges
Several potential limitations could be identified in the present study. During the semi-structured interviews, data could be lost due to cultural beliefs or language barriers on the part of patients. Patient dropout is another possible challenge, given the one-year duration of the study and the requirement to complete interviews at both the beginning and the end of the programme. Additionally, there is a potential for selection bias and the risk of recruiting a sample that may not be sufficiently heterogeneous, as HSCSP primarily serves neighborhoods with middle and upper-middle socioeconomic levels in Barcelona. Nevertheless, the sampling strategy profiles and ensures the study captures a diverse range of experiences.
Conclusion
A comprehensive understanding of the perceptions, expectations, attitudes, needs, and knowledge of patients with MASH can enhance patient-provider communication, support adherence to lifestyle interventions, and improve clinical outcomes. Such insights enable a more personalised approach to multidisciplinary care, ultimately benefiting patient health and the efficient use of healthcare resources.
Footnotes
we are grateful to the participants in the MASH-CVP at HSCSP for their willingness to take part in this study and respond to the questions of the semi-structured interview questions.
ORCID iDs
Ethical Considerations
This study has been approved by the Ethics Committee of Hospital de Sant Pau on April 23st, 2025, under the code 25/093 (OBS). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and national research committee, as well as with the Helsinki Declaration.
Consent to Participate
Informed consent will be obtained from all participants both verbally and in writing, during a face-to-face baseline visit. Participants will be fully informed about the study objectives, procedures, minimal risks, and potential benefits before providing their consent.
Consent for Publication
All participants will provide written informed consent for publication of any individual data, or other details included in this manuscript in the inform consent form. Non-essential identifying information will be omitted to protect participant confidentiality. The original consent forms are securely held by the study investigators and are available upon request.
Author Contributions
M.I.R-L., M.A., and D.M. conceived and designed the study. M.I.R-L., M.A., and G.P-D. contributed to the development of the semi-structured interview guide and the sociodemographic questionnaire. M.I.R-L. and M.A. drafted the manuscript. D.M., G.P-L., I.G., F.M.-M., E.P-C., E.R., M.P., and G.S. critically reviewed the manuscript and approved the final version.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by CIBER – Consorcio Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Relacionadas (CIBERDEM) (CB15/00071), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and the European Union- European Regional Development Fund. M.A. holds a predoctoral grant FI-STEP del Departament de Recerca i Universitats de la Generalitat de Catalunya i el cofinançament pel Fons Social Europeu Plus (2025 STEP 00312). D.M. and M.I.R-L. belong to the XARTEC Salut network and are part of the coordinated consolidated group AGAUR (2021 SGR 00857, and 2021 SGR 01211). I.G. received a grant from the Associació Catalana de Diabetis (ACD), “Ajut a la Recerca Clínica en Diabetis 2023”. Finally, this work has been partially supported by an unrestricted grant from Menarini Spain. Funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data Availability Statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on request.
